Activated leukocyte cell adhesion molecule is a marker for thyroid carcinoma aggressiveness and disease-free survival

Thyroid

Volumn 23, Issue 2, 2013, Pages 201-208

  Chaker, Seham ^a,b   Kak, Ipshita ^a   MacMillan, Christina ^a   Ralhan, Ranju ^a,c   Walfish, Paul G ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CASE REPORT; CELL MEMBRANE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POORLY DIFFERENTIATED THYROID CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROID GLAND; THYROID NODULE; THYROID TUMOR; TUMOR DIFFERENTIATION; UNDIFFERENTIATED CARCINOMA;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; PROGNOSIS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84873676425     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0405     Document Type: Article

References (39)

1. Sipos JA, Mazzaferri EL 2010 Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22:395-404.
2. Ward EM, Jemal A, Chen A 2010 Increasing incidence of thyroid cancer: is diagnostic scrutiny the sole explanation?. Future Oncol 6:185-188.
3. Simard EP, Ward EM, Siegel R, Jemal A 2012 Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62:118-128.
4. National Cancer Institute 2012 Cancer statistics. Bethesda, MD: National Institutes of Health. Available at: www.cancer .gov/statistics (last accessed November 1, 2012).
5. DeLellis RA 2006 Pathology and genetics of thyroid carcinoma. J Surg Oncol 94:662-669.
6. Lin JD, Hsueh C, Chao TC 2009 Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid 19:1053-1059.
7. Tang KT, Lee CH 2010 BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 73:113-128.
8. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
9. Avram AM 2012 Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med 53:754-764.
10. Are C, Shaha A 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453-464.
11. Pelizzo MR, Merante Boschin I, Toniato A, Pagetta C, Casal Ide E, Mian C, Rubello D 2008 Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol 33:359-379.
12. Vaisman A, Orlov S, Yip J, Hu C, Lim T, Dowar M, Freeman JL, Walfish PG 2010 Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 32:689-698.
13. Ofori-Acquah SF, King JA 2008 Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 151:122-128.
14. Weidle UH, Eggle D, Klostermann S, Swart GW 2010 ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics 7:231-243.
15. King JA, Tan F, Mbeunkui F, Chambers Z, Cantrell S, Chen H, Alvarez D, Shevde LA, Ofori-Acquah SF 2010 Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer. Mol Cancer 9:266.
16. van Kempen LC, Nelissen JM, Degen WG, Torensma R, Weidle UH, Bloemers HP, Figdor CG, Swart GW 2001 Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem 276:25783-25790.
17. Swart GW 2002 Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81:313-321.
18. Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke U 1995 Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 181:2213-2220.
19. Degen WG, van Kempen LC, Gijzen EG, van Groningen JJ, van Kooyk Y, Bloemers HP, Swart GW 1998 MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol 152:805-813.
20. Tomita K, van Bokhoven A, Jansen CF, Bussemakers MJ, Schalken JA 2000 Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. Biochem Biophys Res Commun 267:870-874.
21. Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A 2003 ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54:34-43.
22. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG 2004 Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 6:R478-R487.
23. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G 2004 ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57:1160-1164.
24. van den Brand M, Takes RP, Blokpoel-deRuyter M, Slootweg PJ, van Kempen LC 2010 Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma. Oral Oncol 46:393-398.
25. Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R 2005 MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 68:462-470.
26. van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW 2000 Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156:769-774.
27. Ihnen M, Kress K, Kersten JF, Kilic E, Choschzick M, Zander H, Muller V, Mahner S, Janicke F, Woelber L, Milde-Langosch K 2012 Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients. BMC Cancer 12:140.
28. Hong X, Michalski CW, Kong B, Zhang W, Raggi MC, Sauliunaite D, De Oliveira T, Friess H, Kleeff J 2010 ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer. J Surg Oncol 101:564-569.
29. Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, Orengo AM, Puppo A, Ferrini S, Fabbi M 2007 The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 5:1246-1253.
30. Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP 2009 Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer 125:9-14.
31. Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, Vashist YK, Sauter G, Pantel K, Izbicki JR, Bockhorn M 2011 ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer 131:396-405.
32. Micciche F, Da Riva L, Fabbi M, Pilotti S, Mondellini P, Ferrini S, Canevari S, Pierotti MA, Bongarzone I 2011 Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors. PLoS One 6:e17141.
33. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Datta Gupta S, Bahadur S, Siu KW 2008 Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 7: 1162-1173.
34. Ihnen M, Muller V, Wirtz RM, Schroder C, Krenkel S, Witzel I, Lisboa BW, Janicke F, Milde-Langosch K 2008 Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 112:419-427.
35. Hein S, Muller V, Kohler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Ihnen M, Beck K, Issa R, Janicke F, Pantel K, Milde-Langosch K 2011 Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue. Breast Cancer Res Treat 129:347-360.
36. Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S 2008 Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 14:1726-1733.
37. Sawhney M, Matta A, Macha MA, Kaur J, DattaGupta S, Shukla NK, Ralhan R 2009 Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer 124:2098-2105.
38. Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, Koch M, Aigner M, Weitz J 2009 Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 101:457-464.
39. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF 2007 Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104:10158-10163.